α2-macroglobulin inhibits the malignant properties of astrocytoma cells by impeding β-catenin signaling (Cancer Research (2010) 70, (277-87) DOI: 10.1158/0008-5472.CAN-09-1462);α2-macroglobulin inhibits the malignant properties of astrocytoma cells by impeding β-catenin signaling

Cancer Research

Volumn 70, Issue 1, 2010, Pages 277-287

  Lindner, Inge ^a   Hemdan, Nasr Y A ^a,b,c   Buchold, Martin ^a   Huse, Klaus ^d   Bigl, Marina ^a   Oerlecke, Ilka ^a   Ricken, Albert ^a   Gaunitz, Frank ^a   Sack, Ulrich ^a,b   Naumann, Andreas ^b   Hollborn, Margrit ^a   Thal, Dietmar ^e   Gebhardt, Rolf ^a   Birkenmeier, Gerd ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^c Alexandria University Faculty Of Science   (Egypt)

^d FRITZ LIPMANN INSTITUTE   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; BETA CATENIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROTEIN ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN ASSOCIATED PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA CELL; CANCER INHIBITION; CANCER INVASION; CELL ANCHORAGE; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPHEROID CELL; TUMOR CELL; ASTROCYTOMA; CELL ADHESION; CELL MOTION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ALPHA-MACROGLOBULINS; ASTROCYTOMA; BETA CATENIN; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LDL-RECEPTOR RELATED PROTEIN-ASSOCIATED PROTEIN; SIGNAL TRANSDUCTION;

EID: 75149194322     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0036     Document Type: Erratum

References (50)

1. Newton CS, Loukinova E, Mikhailenko I, et al. Platelet-derived growth factor receptor-β (PDGFR-β) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function. J Biol Chem 2005;280: 27872-8.
2. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008;36:184-94.
3. Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 2006;25:35-43.
4. Padmasekar M, Nandigama R, Wartenberg M, Schluter KD, Sauer H. The acute phase protein α2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways. Cardiovasc Res 2007;75:118-28.
5. Arandjelovic S, Freed TA, Gonias SL. Growth factor-binding sequence in human α2-macroglobulin targets the receptor-binding site in transforming growth factor-β. Biochemistry 2003;42:6121-7.
6. LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Cytokine binding and clearance properties of proteinase-activated α2-macroglobulins. Lab Invest 1991;65:3-14.
7. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008;88:887-918.
8. Paczek L, Gaciong Z, Bartlomiejczyk I, Sebekova K, Birkenmeier G, Heidland A. Protease administration decreases enhanced transforming growth factor-β1 content in isolated glomeruli of diabetic rats. Drugs Exp Clin Res 2001;27:141-9.
9. Lauer D, Muller R, Cott C, Otto A, Naumann M, Birkenmeier G. Modulation of growth factor binding properties of α2-macroglobulin by enzyme therapy. Cancer Chemother Pharmacol 2001;47 Suppl:S4-9.
10. Kirsch M, Schackert G, Black PM. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol 2000;50:149-63.
11. Song H, Li Y, Lee J, Schwartz AL, Bu G. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 2009;69:879-86.
12. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-98.
13. Birkenmeier G, Stigbrand T. Production of conformation-specific monoclonal antibodies against α2 macroglobulin and their use for quantitation of total and transformed α2 macroglobulin in human blood. J Immunol Methods 1993;162:59-67.
14. Baumgart Y, Otto A, Schafer A, et al. Characterization of novel monoclonal antibodies for prostate-specific antigen (PSA) with potency to recognize PSA bound to α2-macroglobulin. Clin Chem 2005;51:84-92.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
16. Birkenmeier G, Heidrich K, Glaser C, et al. Different expression of the α2-macroglobulin receptor/low-density lipoprotein receptor-related protein in human keratinocytes and fibroblasts. Arch Dermatol Res 1998;290:561-8.
17. Santel T, Pflug G, Hemdan NY, et al. Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS ONE 2008;3:e3508.
18. Hollenbach M, Hintersdorf A, Huse K, et al. Ethyl pyruvate and ethyl lactate down-regulate the production of pro-inflammatory cytokines and modulate expression of immune receptors. Biochem Pharmacol 2008;76:631-44.
19. Hemdan NY. The role of interleukin-12 in the heavy metal-elicited immunomodulation: relevance of various evaluation methods. J Occup Med Toxicol 2008;3:25.
20. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.
21. Chu CT, Pizzo SV. α2-Macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation. Lab Invest 1994;71:792-812.
22. Sinnreich O, Kratzsch J, Reichenbach A, Glaser C, Huse K, Birkenmeier G. Plasma levels of transforming growth factor-1β and α2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters. Prostate 2004;61:201-8.
23. Williams SE, Ashcom JD, Argraves WS, Strickland DK. A novel mechanism for controlling the activity of α2-macroglobulin receptor/ low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem 1992; 267:9035-40.
24. Pinner S, Sahai E. Imaging amoeboid cancer cell motility in vivo. J Microsc 2008;231:441-5.
25. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004;9:273-85.
26. Wick W, Platten M, Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-β. J Neurooncol 2001;53:177-85.
27. Bacskai BJ, Xia MQ, Strickland DK, Rebeck GW, Hyman BT. The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 2000;97:11551-6.
28. Mantuano E, Mukandala G, Li X, Campana WM, Gonias SL. Molecular dissection of the human α2-macroglobulin subunit reveals domains with antagonistic activities in cell signaling. J Biol Chem 2008;283:19904-11.
29. Stolt PC, Bock HH. Modulation of lipoprotein receptor functions by intracellular adaptor proteins. Cell Signal 2006;18:1560-71.
30. Misra UK, Sharma T, Pizzo SV. Ligation of cell surface-associated glucose-regulated protein 78 by receptor-recognized forms of α2-macroglobulin: activation of p21-activated protein kinase-2-dependent signaling in murine peritoneal macrophages. J Immunol 2005; 175:2525-33.
31. Misra UK, Deedwania R, Pizzo SV. Activation and cross-talk between Akt, NF-κB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J Biol Chem 2006;281:13694-707.
32. Tchetverikov I, Verzijl N, Huizinga TW, TeKoppele JM, Hanemaaijer R, DeGroot J. Active MMPs captured by α 2 macroglobulin as a marker of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2003;21:711-8.
33. Fears CY, Grammer JR, Stewart JE, Jr., et al. Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Res 2005;65: 9338-46.
34. Dedieu S, Langlois B, Devy J, et al. LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities. Mol Cell Biol 2008;28:2980-95.
35. Desrosiers RR, Rivard ME, Grundy PE, Annabi B. Decrease in LDL receptor-related protein expression and function correlates with advanced stages of Wilms tumors. Pediatr Blood Cancer 2006; 46:40-9.
36. Nguyen DH, Webb DJ, Catling AD, et al. Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 2000; 275:19382-8.
37. Webb DJ, Nguyen DH, Gonias SL. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and Matrigel invasion. J Cell Sci 2000;113:123-34.
38. Weaver AM, Hussaini IM, Mazar A, Henkin J, Gonias SL. Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J Biol Chem 1997;272:14372-9.
39. Zhang H, Lee JM, Wang Y, et al. Mutational analysis of the FXNPXY motif within LDL receptor-related protein 1 (LRP1) reveals the functional importance of the tyrosine residues in cell growth regulation and signal transduction. Biochem J 2008;409: 53-64.
40. Li Y, Lu W, Bu G. Essential role of the low density lipoprotein receptor-related protein in vascular smooth muscle cell migration. FEBS Lett 2003;555:346-50.
41. Gao R, Brigstock DR. Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol Res 2003;27:214-20.
42. Spijkers PP, da Costa Martins P, Westein E, Gahmberg CG, Zwaginga JJ, Lenting PJ. LDL-receptor-related protein regulates β2-integrinmediated leukocyte adhesion. Blood 2005;105:170-7.
43. Guo Q, Wu M, Lian P, et al. Synergistic effect of indomethacin andNGX6 on proliferation and invasion by human colorectal cancer cells through modulation of the Wnt/β-catenin signaling pathway. Mol Cell Biochem 2009;330:71-81.
44. Bremnes RM, Veve R, Gabrielson E, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002;20:2417-28.
45. Asano K, Duntsch CD, Zhou Q, et al. Correlation of N-cadherin expression in high grade gliomas with tissue invasion. J Neurooncol 2004;70:3-15.
46. Ulivieri A, Lavra L, Dominici R, et al. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness. J Pathol 2008;215:87-96.
47. Zilberberg A, Yaniv A, Gazit A. The low density lipoprotein receptor-1, LRP1, interacts with the human frizzled-1 (HFz1) and downregulates the canonical Wnt signaling pathway. J Biol Chem 2004; 279:17535-42.
48. Kancha RK, Stearns ME, Hussain MM. Decreased expression of the low density lipoprotein receptor-related protein/α 2-macroglobulin receptor in invasive cell clones derived from human prostate and breast tumor cells. Oncol Res 1994;6:365-72.
49. Hu J, Dong A, Fernandez-Ruiz V, et al. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res 2009;69:6951-9.
50. Birkenmeier G, Muller R, Huse K, et al. Human α2-macroglobulin: genotype-phenotype relation. Exp Neurol 2003;184:153-61.